Jennifer Kayden Lee Sells 1,447 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee sold 1,447 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $85,995.21. Following the completion of the sale, the executive vice president now owns 4,038 shares of the company’s stock, valued at $239,978.34. The trade was a 26.38 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jennifer Kayden Lee also recently made the following trade(s):

• On Monday, November 11th, Jennifer Kayden Lee sold 66,861 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $66.33, for a total transaction of $4,434,890.13.

Rhythm Pharmaceuticals Trading Up 0.9 %

Shares of RYTM stock traded up $0.54 during trading hours on Tuesday, reaching $59.95. The company’s stock had a trading volume of 441,491 shares, compared to its average volume of 515,022. The stock has a market capitalization of $3.68 billion, a P/E ratio of -13.85 and a beta of 2.14. The firm’s fifty day simple moving average is $57.39 and its 200 day simple moving average is $53.13. Rhythm Pharmaceuticals, Inc. has a one year low of $35.17 and a one year high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.07. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The business had revenue of $33.20 million for the quarter, compared to analysts’ expectations of $32.52 million. During the same quarter in the previous year, the business posted ($0.76) earnings per share. The firm’s revenue for the quarter was up 47.6% compared to the same quarter last year. As a group, equities research analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Large investors have recently modified their holdings of the stock. Loomis Sayles & Co. L P bought a new position in Rhythm Pharmaceuticals in the third quarter worth $33,353,000. Alkeon Capital Management LLC grew its position in shares of Rhythm Pharmaceuticals by 16.8% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,167,700 shares of the company’s stock worth $61,176,000 after buying an additional 167,700 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its stake in shares of Rhythm Pharmaceuticals by 14.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,111,043 shares of the company’s stock worth $58,208,000 after acquiring an additional 143,800 shares in the last quarter. Barclays PLC lifted its position in Rhythm Pharmaceuticals by 79.6% during the 3rd quarter. Barclays PLC now owns 106,397 shares of the company’s stock valued at $5,574,000 after acquiring an additional 47,166 shares during the period. Finally, Frazier Life Sciences Management L.P. boosted its stake in Rhythm Pharmaceuticals by 1.9% during the third quarter. Frazier Life Sciences Management L.P. now owns 2,416,952 shares of the company’s stock worth $126,624,000 after acquiring an additional 45,648 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts recently commented on RYTM shares. TD Cowen increased their target price on shares of Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. JMP Securities reaffirmed a “market outperform” rating and set a $75.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. Needham & Company LLC boosted their target price on Rhythm Pharmaceuticals from $55.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Jefferies Financial Group began coverage on Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They set a “buy” rating and a $80.00 price target on the stock. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $80.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 19th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Rhythm Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $68.09.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.